EMA Addresses Rapid Acting Therapies, Psychedelics In Updated Guidance On Depression Treatments

The European Medicines Agency is consulting on major changes to its decade-old guidance on the development of medicinal products for acute and long-term treatment of major depressive disorder.

depression, teen depression, pain, suffering, tunnel
MDD is one of the most common and disabling psychiatric disorders • Source: Shutterstock

The European Medicines Agency is inviting stakeholder feedback on a proposal to update its 10-year-old guidance on developing drugs for treating major depressive disorder (MDD).

The proposed revisions aim to address, among other things, the emergence of new rapid acting antidepressants and the repurposing of...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Europe

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

  • EU Pharma Reform: What You Need to Know Now

     

    As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.

  • New EU Approvals

    <p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>

More from Geography